Menu
Dr. Heather Wakelee is a Professor of Medicine and Chief of the Division of Oncology at Stanford University and Deputy Director of the Stanford Cancer Institute. She is past President of the International Association for the Study of Lung Cancer (IASLC) and is a Fellow of the American Society of Clinical Oncology (FASCO). Dr. Wakelee graduated from Princeton University and Johns Hopkins University School of Medicine and has been at Stanford University since internship. As an experienced investigator, Dr. Wakelee has authored or co-authored more than 300 medical articles on lung cancer and thymic malignancies and is involved in dozens of clinical trials involving adjuvant therapy, immunotherapy (particularly use of immunotherapy in the perioperative setting for NSCLC), and anti-angiogenesis agents. Her research additionally is focused on many specific lung cancer subtypes defined by mutations in genes such as EGFR, ALK, ROS1, RET, BRAF, as well as broad translational efforts.
© 2024 American Society of Clinical Oncology (ASCO®). All Rights Reserved. This content is made available solely for educational and informational purposes and personal use only. Unauthorized reproduction is prohibited.
This selection of presentations does not necessarily represent a balanced view or full discussion of any given subject. The expert perspectives appearing herein was not prepared or reviewed by ASCO and has not been subject to a peer review process. The ideas and opinions expressed herein do not necessarily reflect those of ASCO. The authors, editors, and ASCO are not responsible for errors or omissions in translations. The mention of any company, product, service, or therapy in this collection of materials does not constitute an endorsement of any kind by ASCO. It is the responsibility of the treating physician or other health care provider, relying on independent experience and knowledge of the patient, to determine drug dosages and the best treatment for the patient. Viewers are advised to check the appropriate medical literature and the product information currently provided by the manufacturer of each drug to be administered to verify, among other matters, the dosage, method, and duration of administration, or contraindications. Viewers are also encouraged to contact the manufacturer with questions about the features or limitations of any products. ASCO assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the material contained in this publication or to any errors or omissions.
©2024 American Society of Clinical Oncology (ASCO®). All Rights Reserved.
This content is intended for US healthcare professionals and is made available solely for educational and informational purposes, and personal use only. Unauthorized reproduction is prohibited.
This program is supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. All content has been developed by Springer Healthcare IME in conjunction with independent faculty; financial supporters have had no influence on the educational content.
